Share this page:
Nov 10, 2020
We use RNA interference, or RNAi, to create medicines that silence the genes that cause or contribute to disease. Our goal is to provide life-changing therapies to people living with rare and common diseases.
©| Lexington, MA
Last revised Jan. 2020
Effective 28 December 2021 Dicerna Pharmaceuticals, Inc. is a wholly owned subsidiary of Novo Nordisk A/S